## Chavdar P Krachmarov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7707924/publications.pdf

Version: 2024-02-01

471371 526166 1,344 28 17 27 citations h-index g-index papers 29 29 29 1126 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Sequence-Conserved and Antibody-Accessible Sites in the V1V2 Domain of HIV-1 gp120 Envelope Protein. AIDS Research and Human Retroviruses, 2014, 30, 927-931.	0.5	2
2	Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking. Virology, 2014, 448, 363-374.	1.1	8
3	Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes. Vaccine, 2014, 32, 4916-4924.	1.7	9
4	Computational Prediction of Neutralization Epitopes Targeted by Human Anti-V3 HIV Monoclonal Antibodies. PLoS ONE, 2014, 9, e89987.	1.1	8
5	Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies. Advances in Virology, 2012, 2012, 1-8.	0.5	11
6	Characterization of Structural Features and Diversity of Variable-Region Determinants of Related Quaternary Epitopes Recognized by Human and Rhesus Macaque Monoclonal Antibodies Possessing Unusually Potent Neutralizing Activities. Journal of Virology, 2011, 85, 10730-10740.	1.5	18
7	Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology, 2010, 405, 513-523.	1.1	42
8	Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology, 2009, 392, 82-93.	1.1	38
9	Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Molecular Immunology, 2009, 46, 917-926.	1.0	107
10	Worldwide Distribution of HIV Type 1 Epitopes Recognized by Human Anti-V3 Monoclonal Antibodies. AIDS Research and Human Retroviruses, 2009, 25, 441-450.	0.5	24
11	Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology, 2008, 372, 233-246.	1.1	53
12	Type-Specific Epitopes Targeted by Monoclonal Antibodies with Exceptionally Potent Neutralizing Activities for Selected Strains of Human Immunodeficiency Virus Type 1 Map to a Common Region of the V2 Domain of gp120 and Differ Only at Single Positions from the Clade B Consensus Sequence. Journal of Virology, 2007, 81, 1424-1432.	1.5	63
13	Cross-Clade Neutralizing Activity of Human Anti-V3 Monoclonal Antibodies Derived from the Cells of Individuals Infected with Non-B Clades of Human Immunodeficiency Virus Type 1. Journal of Virology, 2006, 80, 6865-6872.	1.5	113
14	Factors Determining the Breadth and Potency of Neutralization by V3-Specific Human Monoclonal Antibodies Derived from Subjects Infected with Clade A or Clade B Strains of Human Immunodeficiency Virus Type 1. Journal of Virology, 2006, 80, 7127-7135.	1.5	83
15	Antibodies That Are Cross-Reactive for Human Immunodeficiency Virus Type 1 Clade A and Clade B V3 Domains Are Common in Patient Sera from Cameroon, but Their Neutralization Activity Is Usually Restricted by Epitope Masking. Journal of Virology, 2005, 79, 780-790.	1.5	82
16	The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope. Journal of Virology, 2004, 78, 2394-2404.	1.5	111
17	Efficient Isolation of Novel Human Monoclonal Antibodies with Neutralizing Activity Against HIV-1 from Transgenic Mice Expressing Human Ig Loci. Journal of Immunology, 2002, 169, 595-605.	0.4	61
18	Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades. Journal of Virology, 2002, 76, 9035-9045.	1.5	172

#	Article	IF	CITATIONS
19	V3-Specific Polyclonal Antibodies Affinity Purified from Sera of Infected Humans Effectively Neutralize Primary Isolates of Human Immunodeficiency Virus Type 1. AIDS Research and Human Retroviruses, 2001, 17, 1737-1748.	0.5	55
20	Interaction of HIV-1 Tat with Pur? in nuclei of human glial cells: Characterization of RNA-mediated protein-protein binding., 2000, 77, 65-74.		33
21	The single-stranded DNA binding protein, Pur- $\hat{l}_{\pm}$ , binds HIV-1 TAR RNA and activates HIV-1 transcription. Gene, 1998, 210, 37-44.	1.0	70
22	Association of Human Purl± with the Retinoblastoma Protein, Rb, Regulates Binding to the Single-stranded DNA Purl± Recognition Element. Journal of Biological Chemistry, 1995, 270, 24352-24360.	1.6	103
23	Heat-induced morphological and biochemical changes in the nuclear lamina from Ehrlich ascites tumor cells in vivo. Journal of Cellular Biochemistry, 1993, 52, 308-319.	1.2	8
24	Nuclear matrices from transcriptionally active and inactive plant cells. Plant Science, 1991, 76, 35-41.	1.7	9
25	Association of actin with DNA and nuclear matrix from Guerin ascites tumour cells. Molecular and Cellular Biochemistry, 1989, 87, 47-56.	1.4	31
26	Nuclear skeletal structures. Biochemical Education, 1988, 16, 122-127.	0.1	1
27	Isolation and characterization of nuclear lamina from ehrlich ascites tumor cells. Journal of Cellular Biochemistry, 1986, 30, 351-359.	1.2	20
28	Association of DNA with the nuclear lamina in Ehrlich ascites tumor cells. Journal of Cellular Biochemistry, 1986, 31, 59-74.	1.2	9